ASTM-F2065 Standard Practice for Testing for Alternative Pathway Complement Activation in Serum by Solid Materials (Withdrawn 2016)

ASTM-F2065 - 2000 R10 EDITION - SUPERSEDED
Show Complete Document History

Document Center Inc. is an authorized dealer of ASTM standards.
The following bibliographic material is provided to assist you with your purchasing decision:

Standard Practice for Testing for Alternative Pathway Complement Activation in Serum by Solid Materials (Withdrawn 2016)
ORDER

Scope

1.1 This practice provides a protocol for rapid, in vitro screening for alternative pathway complement activating properties of solid materials used in the fabrication of medical devices that will contact blood.

1.2 This practice is intended to evaluate the acute in vitro alternative pathway complement activating properties of solid materials intended for use in contact with blood. For this practice, serum is synonymous with complement.

1.3 This practice consists of two procedural parts. Procedure A describes exposure of solid materials to a standard lot of C4-deficient guinea pig serum [C4(-)GPS], using 0.1-mL serum per 13 × 100-mm disposable glass test tubes. Sepharose CL-4B is used as an example of test materials. Procedure B describes assaying the exposed serum for significant functional alternative pathway complement depletion as compared to control samples. The endpoint in procedure B is lysis of rabbit RBC in buffer containing EGTA and excess Mg++.

1.4 This practice does not address function, elaboration, or depletion of individual complement components except as optional additional confirmatory information that can be acquired using human serum as the complement source. This practice does not address the use of plasma as a source of complement.

1.5 This practice is one of several developed for the assessment of the biocompatibility of materials. Practice F748 may provide guidance for the selection of appropriate methods for testing materials for other aspects of biocompatibility. Practice F1984 provides guidance for testing solid materials for whole complement activation in human serum, but does not discriminate between the classical or alternative pathway of activation.

1.6 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.

Keywords

alternative pathway; biocompatibility; blood compatibility; complement testing; materials; medical devices; Alternative pathway complement activation; Barbitol (veronal) buffer; Biocompatibility; Blood compatibility; Blood materials/applications; C-4 deficient Guidea Pig serum (C4-GPS); Complement activation; Fabrication (of medical devices); Medical devices/equipment; Rabbit RBC (red blood cells); Red blood cells (RBC); Screen analysis--medical/surgical applications; Serum; Sheep RBC (red blood cells); Solid phase materials; in vitro Evaluation; ICS Number Code 11.040.40 (Implants for surgery, prothetics and orthotics)

To find similar documents by ASTM Volume:

13.01 (Medical and Surgical Materials and Devices)

To find similar documents by classification:

11.040.40 (Implants for surgery, prosthetics and orthotics Including pacemakers Ophthalmic implants, see 11.040.70)

This document comes with our free Notification Service, good for the life of the document.

This document is available in either Paper or PDF format.

Document Number

ASTM-F2065-00(2010)

Revision Level

2000 R10 EDITION

Status

Superseded

Modification Type

Withdrawn

Publication Date

Oct. 1, 2010

Document Type

Practice

Page Count

7 pages

Committee Number

F04.16